Hormonal status in protracted critical illness and in-hospital mortality by Sharshar, Tarek et al.
RESEARCH Open Access
Hormonal status in protracted critical illness and
in-hospital mortality
Tarek Sharshar
1*, Sylvie Bastuji-Garin
2, Andrea Polito
1, Bernard De Jonghe
3, Robert D Stevens
4, Virginie Maxime
1,
Pablo Rodriguez
5, Charles Cerf
6, Hervé Outin
3, Philippe Touraine
7, Kathleen Laborde
8,
the Groupe de Réflexion et d’Etude des Neuromyopathies En Réanimation
Abstract
Introduction: The aim of this study was to determine the relationship between hormonal status and mortality in
patients with protracted critical illness.
Methods: We conducted a prospective observational study in four medical and surgical intensive care units (ICUs).
ICU patients who regained consciousness after 7 days of mechanical ventilation were included. Plasma levels of
insulin-like growth factor 1 (IGF-1), prolactin, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing
hormone, estradiol, progesterone, testosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate
(DHEAS) and cortisol were measured on the first day patients were awake and cooperative (day 1). Mean blood
glucose from admission to day 1 was calculated.
Results: We studied 102 patients: 65 men and 37 women (29 of the women were postmenopausal). Twenty-four
patients (24%) died in the hospital. The IGF-1 levels were higher and the cortisol levels were lower in survivors.
Mean blood glucose was lower in women who survived, and DHEA and DHEAS were higher in men who survived.
Conclusions: These results suggest that, on the basis of sex, some endocrine or metabolic markers measured in
the postacute phase of critical illness might have a prognostic value.
Introduction
Critical illness is associated with various endocrinologi-
cal dysfunctions, which has also been linked to increased
mortality, but this association has been reported primar-
ily in acute rather than protracted (>7 days) critical ill-
ness [1-4]. As endocrine status changes with the course
of critical illness [5], the prognostic value of a given hor-
mone may differ between the acute and prolonged
phases. There is an extensive literature on the prognos-
tic value of endocrinological markers in the acute phase
of critical illness, in contrast to the prolonged phase.
Most hormonal studies on protracted critical illness
have either included a small or particular cohort [6] or
assessed one endocrine axis [7]. Therefore, we assessed
the relationships between various endocrine markers
and in-hospital mortality in a large population of
patients with protracted critical illness [8]. The endo-
crine functions that we have assessed included the adre-
nal, thyrotropic, somatotropic and gonadotropic axes, as
they have been shown to be impaired during and after
critical illness [1-4] and play a major role not only in
the response to stress [9,10] but also with regard to
patient outcomes [2,3]. These endocrine markers were
assessed in a study on ICU-acquired paresis [11]
because they affect muscle metabolism. However,
although the present study is based on the same popula-
tion [8,12] and the same hormonal measurements [11]
as previously published ones, its objective (that is, in-
hospital mortality) is entirely original.
Materials and methods
Patients
Briefly, the study was conducted prospectively between
June 2003 and June 2005 in four ICUs (two medical,
one surgical and one medicosurgical). Patients who
required at least mechanical ventilation were screened
* Correspondence: tarek.sharshar@rpc.aphp.fr
1Department of Intensive Care Medicine, AP-HP, Raymond Poincaré Hospital,
University Versailles Saint-Quentin en Yvelines, 104 bd Raymond Poincaré,
Garches F-92380, France
Full list of author information is available at the end of the article
Sharshar et al. Critical Care 2011, 15:R47
http://ccforum.com/content/15/1/R47
© 2011 Sharshar et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.daily for awakening and comprehension using five sim-
ple verbal commands as previously described [13,14].
Patients were enrolled in the study and hormonal assays
were performed on the first day when awakening and
comprehension were satisfactory (day 1). Therefore,
patients without successful awakening were not
included. The study protocol was approved by the Ethics
Committee of Saint-Germain-en-Laye, France. Informed
consent was obtained from all patients.
Demographic characteristics, category of admission,
comorbidities and intensive care unit (ICU) admission
diagnosis were recorded, as well as the severity of criti-
cal illness determined using the Simplified Acute Phy-
siology Score II (SAPS II) [15] and the Organ
Dysfunctions and/or Infection score [16]. The mean
blood glucose levels and the cumulative dose of corti-
costeroids (expressed as hydrocortisone-equivalent
dosage) between ICU admissi o na n di n c l u s i o ni nt h e
study were calculated for each patient.
Endocrinological measurements
Plasma follicle-stimulating hormone (FSH), lutenizing
hormone (LH) and prolactin concentrations were mea-
sured using radioimmunometric assays (RIAs) (Access 2;
Beckman Coulter, Villepinte, France) as described
elsewhere [11]. Plasma concentrations of testosterone,
estradiol and dehydroepiandrosterone (DHEA) were
determined by performing RIA after ether extraction.
Plasma concentrations of dehydroepiandrosterone sul-
fate (DHEAS), progesterone, cortisol and insulin-like
growth factor 1 (IGF-1) were measured directly by RIA
(CIS Bio International, Gif-sur-Yvette, France). Plasma
cortisol levels measured in patients still being treated
with hydrocortisone were not taken into account in the
analysis. Plasma concentrations of thyroid-stimulating
h o r m o n ew e r ed e t e r m i n e db yu s i n gat h i r d - g e n e r a t i o n
sandwich immunoassay (Immunotech Beckman Coulter,
Villepinte, France). Plasma levels were considered
abnormally low when they were below the lowest nor-
mal value.
In men, independently of age, hypogonadism was con-
sidered when plasma testosterone levels were below
3 ng/ml [17]. Hypogonadism was considered secondary
(SH) when FSH and LH concentrations were below
5 mU/l and primary (PH) when FSH and LH levels were
above 10 mIU/l [17].
Women were considered postmenopausal if they were
older than 55 years of age or if they reported amenor-
rhea for 1 year or more. Because of the small number of
premenopausal women (n = 8), sex-dependent hor-
mones were analyzed only in postmenopausal women.
In postmenopausal women, PH was considered to be
the rule. Hypogonadism was considered SH when LH
and FSH levels were inappropriately low (<10 mIU/l) in
the presence of a low estradiol level (<10 pg/ml) in post-
menopausal women [17].
Mortality
The end point of the study was in-hospital mortality.
Therefore, we assessed the association of in-hospital
mortality with day 1 plasma levels of nongonadic hor-
mones measured in the whole population and of gona-
dic hormones separately for postmenopausal women
and men. For each nonsurvivor, the cause of death was
determined by two independent observers on the basis
of a review of the medical notes and charts, and deaths
were classified as being due to sepsis or not. Deaths
attributed to infection were those in which an infection-
related complication developed after initial awakening,
including septic shock, multiple organ failure, acute
respiratory distress syndrome and hypoxemic pneumo-
nia. Cases in which death was associated with a decision
to limit or withdraw care were also recorded [18].
Statistical analyses
Variables were recorded upon admission, between
admission and awakening, at awakening (hormonal data)
and at discharge (Tables 1 and 2). Continuous variables
were not dichotomized and were reported as medians
with interquartile ranges, and categorical variables were
coded as 1 or 0 and reported as percentages. The
Mann-Whitney U test was used for comparison of con-
tinuous variables, and the c
2 or Fisher’se x a c tt e s tw a s
used to assess categorical variables.
Survivors and nonsurvivors were compared on a priori
selected variables, including sex, age, SAPS II and hor-
monal measurements (Table 2). Odds ratios (ORs) and
95% confidence intervals (95% CIs) were estimated by
using exact logistic regression models for variables asso-
ciated with survival with P < 0.05. ORs were stratified
by sex for gonadic hormones. Because of the low num-
ber of events, multivariate analysis including variables
associated with in-hospital mortality could not be
performed.
P ≤ 0.05 was considered statistically significant. All
significance tests were two-tailed. Data were analyzed
using the Stata release 8.0 software (StataCorp. 2003,
College Station, TX, USA) and the StatXact and Log-
Xact software programs (Cytel Inc., Cambridge, Massa-
chussets, USA).
Results
Patients’ characteristics
The study patients’ characteristics are presented in
Table 1. Twenty-four patients (24%) died in the hospital,
including 15 in the ICU. Fourteen patients (58%) died as
a result of an infection-related complication that devel-
oped after initial awakening. Six patients (25%) died as a
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ciency, three patients (13%) died as a result of sudden
death and one patient (4%) died as a result of general-
ized cancer. A decision to limit or withdraw life-sustain-
ing measures was made in 11 patients.
In the overall population, in-hospital mortality was
significantly associated with female sex and a higher day
1 SAPS II (Table 2). In-hospital nonsurvivors had signif-
icantly higher plasma cortisol levels and lower plasma
IGF-1 levels than in-hospital survivors. Mean blood
glucose levels between admission and awakening tended
to be greater in in-hospital nonsurvivors.
Mean blood glucose levels were significantly higher in
women who were nonsurvivors. Other plasma hormone
levels, as well as the prevalence of SH, did not differ at
a statistically significant level between the two groups.
In men, plasma levels of DHEA and DHEAS were sig-
nificantly lower in nonsurvivors. The proportion of men
with SH and PH, as well as plasma levels of gonadic
hormones and mean blood glucose, did not show a sta-
tistically significant difference between the two groups.
Discussion
Protracted critical illness is associated with dysfunction
of the neuroendocrine axes and the adrenal gland
[5,6,17,19-21], which is characterized by low circulating
levels of hypophyseal and adrenal hormones, notably
DHEA and DHEAS. In accord with our previous study
[11], the present results are consistent with this endo-
crine pattern, indicating that hormonal status has been
assessed at the postacute phase of critical illness.
We found that nonsurvivors had increased plasma
cortisol levels, suggesting persisting stress. Increased
plasma cortisol level was associated with decreased
plasma DHEA and DHEAS levels in men who subse-
quently died, suggesting adrenal exhaustion [22].
Although the association of mortality with adrenal
exhaustion has also been reported previously in septic
shock [1,2], we do not have any explanation for the fact
that it was observed only in men in the present study.
Interestingly, neither high circulating cortisol levels nor
adrenal exhaustion were related to the administration of
corticosteroids, suggesting that corticosteroid therapy
has no deleterious effect on adrenal function. This is an
important finding, considering the controversy regarding
the usefulness of corticosteroids in patients in septic
shock [23]. Arlt et al. [1] previously showed a lack of
association between DHEA (increased) and DHEAS
(decreased) and that mortality was associated with an
increased cortisol-to-DHEA ratio. However, these results
were obtained when patients were in an early stage of
septic shock. Conversely, Marx et al. [2] measured the
plasma levels of adrenocortical hormones in 30 patients
at the onset, the halfway point and the last day of sepsis,
with a total duration of about 9 days. On the last day of
sepsis, they found that plasma levels of cortisol and
DHEA tended to be higher and those of DHEAS were
lower in nonsurvivors. The discrepancy between the
DHEA findings between the study by Marx et al.a n d
our study might result from differences in the popula-
tions studied, especially with regard to admission diag-
nosis (sepsis vs. critical illness) and male-to-female sex
ratio. The immune system-activating properties of
DHEA may account for the association of DHEA levels
with mortality [1,2]. These findings would support an
assessment of the benefit of DHEA treatment in the
postacute phase of critical illness, notably in men [24].
We found that in-hospital mortality was associated
with low plasma IGF-1 levels. To our knowledge, this
postacute phase relationship has been assessed in only
one small cohort study [6]. A low IGF-1 level is consid-
ered a valuable marker of growth hormone (GH) defi-
ciency, which is considered deleterious [25] and has
Table 1 Patients’ clinical characteristics and outcomes
a
Patient demographics, N = 102 (100%) Data
Median age, yr (IQR) 66 (51 to 78)
COPD
b, n (%) 39 (38%)
Chronic cardiac insufficiency
b, n (%) 28 (27.5%)
Medical admission, n (%) 71 (69.6%)
Median SAPS II at ICU admission (IQR) 46 (38 to 55)
From admission to awakening (day 1)
Septic shock
c, n (%) 53 (52%)
Median days with failure of ≥2 organs
d, days (IQR) 8 (7 to 11)
Median duration of mechanical ventilation, days
(IQR)
10.0 (8.0 to
14.0)
Mean blood glucose, mM/l (IQR) 7.6 (6.9 to 8.8)
Use of vasopressors, n (%) 77 (75%)
Use of corticosteroids, n (%) 64 (63%)
Median corticosteroid dose, 10
3 g (IQR) 1.0 (0 to 1.9)
Median delay from steroid administration to day 1,
days (IQR)
3.0 (1.0 to 8.0)
Use of NMBA, n (%) 40 (39%)
At awakening (day 1, n = 86)
Median SAPS II (IQR) 30 (23 to 26)
After awakening
Median ICU length of stay, days (IQR) 23 (15 to 35)
ICU mortality, n (%) 15 (15%)
In-hospital mortality, n (%) 24 (24%)
aIQR, interquartile range; COPD, chronic obstructive pulmonary disease; ICU,
intensive care unit; SAPS II, Simplified Acute Physiology Score II [15]; NMBA,
neuromuscular blocking agent;
bdiagnosis of COPD and chronic cardiac
insufficiency were based on clinical history;
cseptic shock was defined as the
administration of catecholamines and a concomitant documented infection
after exclusion of other causes of shock;
drenal, hepatic, and hematological
failure were defined according to the Organ Dysfunctions and/or Infection
score [16].
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mized clinical trial has shown that the administration of
GH increased mortality in critically ill patients [26].
Because GH was administered during the acute phase of
critical illness in the Takala et al.t r i a l[ 2 6 ] ,o n em a y
argue that GH administration should be tested during
the prolonged phase of critical illness. Moreover, it has
recently been shown that critical illness-associated mor-
tality was not associated with IGF-1 level but with
increased GH level (measured in the acute phase) [28].
It has to be noted that decreases in circulating IGF-1
levels can result from various causes frequently
Table 2 Comparison between hospital survivors and nonsurvivors
a
Patient demographics, N = 102 (100%) Hospital survivors (n = 78) Hospital nonsurvivors (n = 24) P value
b OR (95% CI)
c
Women, n (%) 24 (30.8) 13 (54.2) 0.05 2.7 (0.97 to 6.8)
Median age, yr (IQR) 62 (47 to 77) 69 (58 to 80) 0.13
From admission to awakening (day 1)
Mean blood glucose
d, mM/l (IQR) 7.6 (6.8 to 8.6) 8.3 (7.2 to 9.7) 0.07 1.2 (0.95 to 1.4)
Women 8.0 (7.0 to 8.7) 9.4 (7.8 to 11.1) 0.03 1.5 (0.98 to 2.2)
Men 7.4 (6.7 to 8.6) 7.2 (6.7 to 8.7) 0.89
At awakening (day 1)
Median SAPS II (IQR) 28 (21 to 34) 35 (29 to 41) 0.007 1.1 (1.0 to 1.1)
Median FSH
e, mIU/ml (IQR)
Women 2.9 (0.75 to 17.9) 1.6 (0.68 to 4.7) 0.41
Men 3.9 (1.9 to 7.6) 3.8 (1.6 to 6.5) 0.93
Median LH
e, mIU/ml (IQR)
Women 0.35 (0.2 to 3.0) 0.21 (0.21 to 1.2) 0.61
Men 4.35 (2.2 to 6.5) 6.9 (0.63 to 13) 0.56
Median prolactin, ng/ml (IQR) 9.5 (5.2 to 16) 8.3 (5.1 to 15) 0.54
Median estradiol
e, pg/ml (IQR)
Women 10 (10 to 28) 10 (10 to 12) 0.82
Men 14.5 (10 to 23) 10 (10 to 24) 0.79
Median testosterone
e, ng/ml (IQR)
Women 0.09 (0.07 to 0.18) 0.07 (0.07 to 0.16) 0.81
Men 0.78 (0.35 to 1.70) 0.63 (0.43 to 1.1) 0.57
Median cortisol
f, ng/ml (IQR) 16.0 (12.0 to 23.0) 23.0 (18.5 to 34.5) 0.01 4.3 (1.5 to 12.1)
Women 15.5 (12.0 to 25.0) 23.0 (20.0 to 25.0)
Men 16.0 (12.0 to 23.0) 22.0 (14.0 to 41.5)
Median DHEA
e, ng/ml (IQR)
Women 0.30 (0.30 to 0.66) 0.30 (0.30 to 0.89) 0.50
Men 0.59 (0.30 to 1.80) 0.30 (0.30 to 0.45) 0.01 0.2 (0.04 to 0.97)
Median DHEAS
e, ng/ml (IQR)
Women 262 (107 to 469) 366 (79 to 580) 0.86
Men 486 (184 to 1,141) 198 (100 to 310) 0.04 0.2 (0.03 to 0.8)
Median progesterone, ng/ml (IQR)
Women 0.23 (0.05 to 0.29) 0.24 (0.04 to 0.69) 0.49
Median SH (%) 57 (73%) 18 (75%) 1.00
Median PH (%)
Men 19 (35%) 6 (55%) 0.31
Median TSH, mIU/ml (IQR) 1.25 (0.52 to 2.35) 1.34 (0.74 to 2.12) 0.68
Median IGF-1, ng/ml (IQR) 78 (56 to 112) 65 (46 to 70) 0.007 0.2 (0.07 to 0.6)
Women 73.5 (50.5 to 113.5) 59.5 (57.5 to 69.0)
Men 81 (59 to 111) 65.0 (50.0 to 73.0)
aSAPS, Simplified Acute Physiology Score II [15]; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH,
luteinizing hormone; TSH, thyroid-stimulating hormone; IGF-1, insulin-like growth factor 1; SH secondary hypogonadism; PH, primary hypogonadism; IQR,
interquartile range; OR, odds ratio; 95% CI, 95% confidence interval;
bP values were derived from performing the Mann-Whitney U test or Fisher’s exact test as
appropriate;
cOR and 95% CI were estimated by using exact logistic regression models;
dORs estimated after dichotomization on median value;
eassessed in 85
patients, including 56 men and 29 postmenopausal women, among whom 11 men and 11 women died in the hospital, respectively;
fplasma cortisol levels of 83
patients were taken into account in the analysis; the other 19 patients were still being treated with hydrocortisone at the time the blood sample was taken and
thus were excluded from the cortisol measurement.
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tion, chronic liver disease or diabetes [17]. In contrast
to previous reports [29,30], we did not find that plasma
IGF-1 levels differed between women and men.
Female sex and increased blood glucose levels have
been shown to be independently associated with
increased mortality [31-33]. Therefore, these relation-
ships can support our finding that blood glucose levels
were higher in women who did not survive. It is also
known that menopause is associated with type 2 dia-
betes mellitus. Preexisting diabetes was not more fre-
quent in female patients who did not survive. It is
conceivable that the conjunction of menopause and cri-
tical illness induce insulin resistance. Although such a
benefit has not been reported in a large trial [34,35], it
would be worth assessing the effect of strict glucose
control in postmenopausal female patients in the ICU.
Limitations of the study
The biological effects of hormones depend not only on
their circulating levels but also on specific and nonspeci-
fic hormone-binding proteins and on the expression and
regulation of hormone receptors. Since we did not
assess binding protein levels or hormone receptor activ-
ity, we cannot exclude that a given hormone is asso-
ciated with mortality on the basis of serum levels alone.
Similarly, tissue hormone levels might also have a prog-
nostic value, but obviously they are not assessable in a
living patient. Thus, Arem et al. [36] found that tissue
thyroid hormone levels were lower in most organs of
more patients who died as a result of critical illness
than in those of patients who died as a result of trauma.
Finally, single circulating levels of hormones must be
interpreted with caution because these levels may fluctu-
ate with time, and dynamic assessments were not per-
formed in the present study [17]. Similarly, assessment
of pulsatile secretion of hypothalamohypophyseal hor-
mones would also have been interesting. Because such
assessments require repeated measurements, compre-
hensive hormonal studies have included a relatively
small number of patients [37].
We acknowledge that a statistical association does not
signify a causal relationship. Endocrinological dysfunc-
tion and mortality might be two independent conse-
quences of critical illness. Because of the relatively low
number of events, we did not perform multivariate ana-
lyses to determine whether endocrinological dysfunction
was independently associated with in-hospital mortality.
It is also possible that a larger patient cohort would
have allowed us to identify other endocrinological fac-
tors. Despite these limitations, our study remains origi-
nal, as we have assessed the relationships between
various hormones and mortality at the postacute phase
of critical illness in a patient cohort that is relatively
large in comparison with other similar studies. It has to
be noted that hormones were not chosen at random,
but rather because they might affect outcomes, includ-
ing even gonadotropic hormones [3,38].
We have used the term “protracted” because assess-
ment of plasma hormone levels was done after the
seventh day of critical illness. Indeed, this time point is
often used to discriminate the acute phase from the
postacute phase of critical illness. We acknowledge that
this definition is too simple, because “time” is not the
same for all patients and all types of critical illness.
From a clinical point of view, awakening is a major
milestone in the course of critical illness. It often indi-
cates recovery, and it is a time when important thera-
peutic decisions are made, such ventilator weaning or
physiotherapy.
Conclusions
We found that in-hospital mortality was associated with
high plasma cortisol and low plasma IGF-1 levels in the
whole patient population, with low plasma DHEA and
DHEAS levels in men and with increased blood glucose
levels in women. Before attempting to conduct a clinical
trial on hormonal therapy, we think that these associa-
tions should be confirmed in a larger patient cohort and
that their pathogenic mechanisms should be elucidated.
Key messages
￿ The impact of endocrinological dysfunction in the
postacute phase of critical illness has been scantly
assessed.
￿ The adrenal, thyrotropic, somatotropic and gona-
dotropic axes were assessed in 102 patients (65 men
and 37 women) who had required mechanical venti-
lation for at least seven days (median, 10 days).
￿ The in-hospital mortality rate was 24%.
￿ The plasma level of IGF-1 was higher and that of
cortisol was lower in survivors, regardless of sex.
￿ Plasma levels of DHEA and DHEAS were higher in
men who survived.
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